Two-Year Results of Intravitreal Bevacizumab Injection in Retinal Vein Occlusion.

Lee, Young Seob; Kim, Moo Sang; Yu, Seung Young; Kwak, Hyung Woo

doi:2011.52.9.1039

J Korean Ophthalmol Soc > Volume 52(9); 2011 > Article

Original Article

Journal of the Korean Ophthalmological Society 2011;52(9):1039-1047.
DOI: https://doi.org/10.3341/jkos.2011.52.9.1039 Published online September 15, 2011.

Two-Year Results of Intravitreal Bevacizumab Injection in Retinal Vein Occlusion.

Young Seob Lee, Moo Sang Kim, Seung Young Yu, Hyung Woo Kwak

¹Department of Ophthalmology, Kyung Hee University School of Medicine, Seoul, Korea. syyu@khu.ac.kr
²Department of Ophthalmology, Inje University College of Medicine, Seoul, Korea.

망막정맥폐쇄 환자에서 유리체내 베바시주맙 주입술의 2년 임상 결과

이영섭¹⋅김무상²⋅유승영¹⋅곽형우¹

Department of Ophthalmology, Kyung Hee University School of Medicine¹, Seoul, Korea Department of Ophthalmology, Inje University College of Medicine², Seoul, Korea

Abstract

PURPOSE
The authors evaluated the 2-year clinical results of intravitreal bevacizumab injection in retinal vein occlusion (RVO). METHODS: Thirty-two eyes of 32 patients treated with an intravitreal bevacizumab injection of 1.25 mg (0.05 ml) for RVO (branch RVO: 22 eyes, central RVO: 10 eyes), repeated 3 times at a 6-week interval and were available for a follow-up period of at least 2 years were retrospectively reviewed. Best-corrected visual acuity (BCVA) before treatment and 6, 12, and 24 months after 3 serial injections, was recorded. The optical coherence tomography (OCT) results were analyzed to identify prognostic factors for recurrent macular edema that needed reinjection. RESULTS: Two years after the treatment, mean BCVA was significantly improved (p = 0.000). Out of 32 eyes, 16 (branch RVO: 8 eyes; central RVO: 8 eyes) needed reinjection because of recurrent macular edema. In central RVO, a significantly high reinjection rate was shown in serous retinal detachment (SRD) compared with cystoid macular edema (CME) as identified in OCT findings (p = 0.049). Additionally, in branch RVO, a high reinjection rate was shown in SRD, although statistically not significant (p = 0.375). CONCLUSIONS: In patients with RVO, a significant visual improvement was maintained for at least 2 years after intravitreal bevacizumab injection. Based on OCT results, SRD showed a high reinjection rate compared with CME in CRVO.

Key Words: Bevacizumab;Macular edema;OCT results;Retinal vein occlusion;Two-year results